CoChat

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Gene therapy for lipoprotein lipase deficiency

Gaudet, Daniel, Méthot, Julie, Kastelein, John · 2012 · Current Opinion in Lipidology

Abstract

PURPOSE OF REVIEW: The present review summarizes the clinical development of adeno-associated viral vector (AAV)1-lipoprotein lipase (LPL)S447X gene therapy (alipogene tiparvovec) for lipoprotein lipase deficiency. Lipoprotein lipase deficiency is a rare inherited disease characterized by severe hypertriglyceridaemia, chylomicronaemia and risk of recurrent pancreatitis or other complications. AAV1-LPLS447X gene therapy is based on the rationale that by adding episomal copies of functional LPL genes into muscle cells lacking active LPL, metabolic function could be improved or restored. RECENT FINDINGS: AAV1-LPLS447X is a nonreplicating and nonintegrating AAV of serotype 1 designed to deliver and express the human LPL gene variant S447X. The clinical development programme for AAV1-LPLS447X consisted of two observational studies, three open-label interventional studies and one case note review analysis. Intramuscular administration of AAV1-LPLS447X was generally well tolerated and was associated with reduction in overall pancreatitis incidence and signs of clinical improvement up to 2 years after administration. Results of interventional studies suggest that markers of postprandial metabolism could be more accurate than fasting plasma triglyceride concentration to monitor the effect of AAV1-LPLS447X . SUMMARY: The overall benefit-risk ratio of AAV1-LPLS447X gene therapy appears positive to date, particularly for the patients presenting the highest risk of complications.

Overview

Integrity signals

Registry

Crossref · 10.1097/mol.0b013e3283555a7e

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 41 references

Research works printed but not linked: 1

  1. Mingozzi, 2011, Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 2011; 12:341-355., Erratum in: Nat Rev Genet, 12, 515

Cited by

See all 181

Metadata

Authors
Gaudet, D., Méthot, J., & Kastelein, J.
Affiliations
  • Hôpital de Chicoutimi (CA)
  • Amsterdam UMC Location University of Amsterdam (NL)
Corresponding author
Gaudet, Daniel
Venue
Current Opinion in Lipidology
Published
2012-08
Volume
23
Issue
4
Pages
310-320
ISSN
0957-9672 (ISSN-L)
OpenAlex
W2019818397
Cited by
178
References
40
Citations by year
2026: 2 · 2025: 14 · 2024: 4 · 2023: 6 · 2022: 11 · 2021: 32 · 2020: 5 · 2019: 12 · 2018: 11 · 2017: 14 · 2016: 18 · 2015: 19 · 2014: 15 · 2013: 14 · 2012: 1
FWCI
2.56
Type
journal article
Language
en
Open access
closed
Locations
  • Current Opinion in Lipidology (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Funders
Canadian Institutes of Health Research (CTP82941)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
lipoprotein lipase deficiency, gene therapy, hypertriglyceridemia, pancreatitis, intramuscular gene delivery, clinical trial results
MeSH terms
Dependovirus, Animals, Genetic Vectors, Humans, Lipoprotein Lipase, Safety, Genetic Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gene therapy for lipoprotein lipase deficiency. https://app.cochat.ai/papers/10.1097/mol.0b013e3283555a7e
The paper
Gaudet, D., Méthot, J., & Kastelein, J. (2012). Gene therapy for lipoprotein lipase deficiency. Current Opinion in Lipidology. https://doi.org/10.1097/mol.0b013e3283555a7e

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.